|
|
|
|
|
|
|
Ashish Kamat, MD, MBBS
|
Professor of Urology and Cancer Research and President of International Bladder Cancer Group, Ashish Kamat leads a collaborative effort of rapid-fire expert debates of selected topics of interest in urothelial carcinoma. Leaders in the field discuss complex clinical changes in treating patients with bladder cancer, treatment alternatives in different bladder cancer disease states, rationales for selecting particular therapy when a variety of
treatment options exist and clinical implications for diagnosis and prognosis.
|
|
|
|
|
|
|
|
|
| Bladder Cancer Expert Debates
|
|
|
|
|
|
|
|
|
Management of High-Grade T1 Bladder Cancer: Cystectomy versus BCG
|
Bernard H. Bochner, MD, FACS and Paolo Gontero, MD
Ashish Kamat welcomes Paolo Gontero and Bernard Bochner to engage in a debate considering a hypothetical patient with nonmuscle invasive high-grade T1 disease.
|
|
|
|
|
|
|
|
|
|
|
|
A Debate on the Management of BCG Unresponsive - Cystectomy Ineligible Bladder Cancer Patients: Pembrolizumab Vs. Nadofaragene Firadenovec
|
Arjun V. Balar, MD and Peter Black, MD
Arjun Balar and Peter Black join Ashish Kamat to consider the use of nadofaragene firadenovec versus pembrolizumab for a patient with BCG unresponsive carcinoma in situ in the bladder where the patient is ineligible for a cystectomy.
|
|
|
|
|
|
|
|
|
|
|
|
Neoadjuvant Vs. Adjuvant Chemotherapy in Upper Tract Urothelial Carcinoma
|
Alison J. Birtle, MD, MBBS, MRCP, FRCR, BSc and Surena F. Matin, MD
Alison Birtle and Surena Matin join Ashish Kamat for an educational session on the highly debated question of “should we use neoadjuvant or adjuvant therapy when it comes to upper tract urothelial carcinoma?
|
|
|
|
|
|
|
|
|
|
|
|
T2 Muscle-Invasive Bladder Cancer: Tri-Modality Therapy (TMT) versus Radical Cystectomy
|
Stephen B. Williams, MD and Nicholas James, MBBS, FRCP, FRCR, Ph.D.
In this conversation, the use of trimodal therapy versus radical cystectomy for treating T2 bladder cancer is debated by Stephen Williams and Nicholas James.
|
|
|
|
|
|
|
|
|
|
|
| Neoadjuvant Immune-Checkpoint Inhibition Vs. Neoadjuvant Cisplatin-Based Chemotherapy for Muscle Invasive Bladder Cancer (MIBC) |
Andrea Necchi, MD and Petros Grivas, MD, Ph.D.
Ashish Kamat moderates a debate between Andrea Necchi and Petros Grivas on current and emerging treatment options for muscle-invasive bladder cancer. |
|
|
|
|
|
|
|
|
|
|
|
Blue Light Cystoscopy with Cysview® & Adjuvant Perioperative Chemotherapy for Nonmuscle-Invasive Bladder Cancer
|
Siamak Daneshmand, MD and Trinity J. Bivalacqua, MD, Ph.D.
Sia Daneshmand and Trinity Bivalacqua compare the benefits of enhanced cystoscopy with blue light cystoscopy in TURBT to the benefits of perioperative chemotherapy following TURBT.
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
